775 related articles for article (PubMed ID: 28687375)
21. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
[TBL] [Abstract][Full Text] [Related]
22. Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent disease.
Nanda T; Yaeh A; Wu CC; Jani A; Saad S; Qureshi YH; Cauley KA; Lesser J; Cheng SK; Isaacson SR; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lassman AB; Wang TJC
J Neurooncol; 2018 Jan; 136(2):281-287. PubMed ID: 29170908
[TBL] [Abstract][Full Text] [Related]
23. Postoperative stereotactic radiosurgery for resected brain metastases: A comparison of outcomes for large resection cavities.
Zhong J; Ferris MJ; Switchenko J; Press RH; Buchwald Z; Olson JJ; Eaton BR; Curran WJ; Shu HG; Crocker IR; Patel KR
Pract Radiat Oncol; 2017; 7(6):e419-e425. PubMed ID: 28668668
[TBL] [Abstract][Full Text] [Related]
24. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis.
Prabhu RS; Press RH; Patel KR; Boselli DM; Symanowski JT; Lankford SP; McCammon RJ; Moeller BJ; Heinzerling JH; Fasola CE; Asher AL; Sumrall AL; Buchwald ZS; Curran WJ; Shu HG; Crocker I; Burri SH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):459-467. PubMed ID: 28871997
[TBL] [Abstract][Full Text] [Related]
25. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases?
Chang WS; Kim HY; Chang JW; Park YG; Chang JH
J Neurosurg; 2010 Dec; 113 Suppl():73-8. PubMed ID: 21121789
[TBL] [Abstract][Full Text] [Related]
26. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.
Kirkpatrick JP; Wang Z; Sampson JH; McSherry F; Herndon JE; Allen KJ; Duffy E; Hoang JK; Chang Z; Yoo DS; Kelsey CR; Yin FF
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):100-8. PubMed ID: 25442342
[TBL] [Abstract][Full Text] [Related]
27. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
[TBL] [Abstract][Full Text] [Related]
28. Local recurrence patterns after postoperative stereotactic radiation surgery to resected brain metastases: A quantitative analysis to guide target delineation.
Gui C; Moore J; Grimm J; Kleinberg L; McNutt T; Shen C; Chen L; Bettegowda C; Lim M; Redmond KJ
Pract Radiat Oncol; 2018; 8(6):388-396. PubMed ID: 30029965
[TBL] [Abstract][Full Text] [Related]
29. Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional Analysis.
Patel KR; Burri SH; Asher AL; Crocker IR; Fraser RW; Zhang C; Chen Z; Kandula S; Zhong J; Press RH; Olson JJ; Oyesiku NM; Wait SD; Curran WJ; Shu HK; Prabhu RS
Neurosurgery; 2016 Aug; 79(2):279-85. PubMed ID: 26528673
[TBL] [Abstract][Full Text] [Related]
30. Whole Brain Radiotherapy Versus Stereotactic Radiosurgery in Poor-Prognosis Patients with One to 10 Brain Metastases: A Randomised Feasibility Study.
Raman S; Mou B; Hsu F; Valev B; Cheung A; Vallières I; Ma R; McKenzie M; Beaton L; Rackley T; Gondara L; Nichol A
Clin Oncol (R Coll Radiol); 2020 Jul; 32(7):442-451. PubMed ID: 32085923
[TBL] [Abstract][Full Text] [Related]
31. Resection and brain brachytherapy with permanent iodine-125 sources for brain metastasis.
Raleigh DR; Seymour ZA; Tomlin B; Theodosopoulos PV; Berger MS; Aghi MK; Geneser SE; Krishnamurthy D; Fogh SE; Sneed PK; McDermott MW
J Neurosurg; 2017 Jun; 126(6):1749-1755. PubMed ID: 27367240
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis.
Lamba N; Muskens IS; DiRisio AC; Meijer L; Briceno V; Edrees H; Aslam B; Minhas S; Verhoeff JJC; Kleynen CE; Smith TR; Mekary RA; Broekman ML
Radiat Oncol; 2017 Jun; 12(1):106. PubMed ID: 28646895
[TBL] [Abstract][Full Text] [Related]
33. Gamma Knife radiosurgery to the surgical cavity following resection of brain metastases.
Jagannathan J; Yen CP; Ray DK; Schlesinger D; Oskouian RJ; Pouratian N; Shaffrey ME; Larner J; Sheehan JP
J Neurosurg; 2009 Sep; 111(3):431-8. PubMed ID: 19361267
[TBL] [Abstract][Full Text] [Related]
34. Cavity volume dynamics after resection of brain metastases and timing of postresection cavity stereotactic radiosurgery.
Atalar B; Choi CY; Harsh GR; Chang SD; Gibbs IC; Adler JR; Soltys SG
Neurosurgery; 2013 Feb; 72(2):180-5; discussion 185. PubMed ID: 23149969
[TBL] [Abstract][Full Text] [Related]
35. Postsurgical Cavity Evolution After Brain Metastasis Resection: How Soon Should Postoperative Radiosurgery Follow?
Patel RA; Lock D; Helenowski IB; Chandler JP; Sachdev S; Tate MC; Kruser TJ
World Neurosurg; 2018 Feb; 110():e310-e314. PubMed ID: 29122731
[TBL] [Abstract][Full Text] [Related]
36. Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases.
Minniti G; Esposito V; Clarke E; Scaringi C; Lanzetta G; Salvati M; Raco A; Bozzao A; Maurizi Enrici R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):623-9. PubMed ID: 23683828
[TBL] [Abstract][Full Text] [Related]
37. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J; Holm T; Pettersson D; Berglund Å; Cedermark B; Radu C; Johansson H; Machado M; Hjern F; Hallböök O; Syk I; Glimelius B; Martling A
Lancet Oncol; 2017 Mar; 18(3):336-346. PubMed ID: 28190762
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.
Henderson MA; Burmeister BH; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2015 Sep; 16(9):1049-1060. PubMed ID: 26206146
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.
Brennan C; Yang TJ; Hilden P; Zhang Z; Chan K; Yamada Y; Chan TA; Lymberis SC; Narayana A; Tabar V; Gutin PH; Ballangrud Å; Lis E; Beal K
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):130-6. PubMed ID: 24331659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
